Neurizon Therapeutics Raises AU$2.7 Million Through Entitlement Offer Shortfall
Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotechnology company dedicated to addressing neurodegenerative diseases, has raised around AU$2.7 million through the placement of the shortfall from its recent entitlement offer. This additional funding strengthens the company's balance sheet and enhances its ability to continue advancing its lead drug candidate, NUZ-001, for the treatment of ALS. The Entitlement Offer, which sought to raise up to AU$17.1 million, closed with a shortfall of approximately AU$11.3 million. The funds raised will support ongoing clinical development, commercialisation of NUZ-001, and working capital needs, potentially reducing reliance on its convertible note facility. The company remains on track with its clinical and regulatory milestones and is committed to the HEALEY ALS Platform Trial. Neurizon is positioning NUZ-001 for future commercialization while expanding its focus on broader neurodegenerative diseases.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Neurizon Therapeutics Raises AU$2.7 Million Through Entitlement Offer Shortfall
Neurizon Therapeutics Limited (ASX: NUZ), a clinical-stage biotechnology company dedicated to addressing neurodegenerative diseases, has raised around AU$2.7 million through the placement of the shortfall from its recent entitlement offer. This additional funding strengthens the company's balance sheet and enhances its ability to continue advancing its lead drug candidate, NUZ-001, for the treatment of ALS. The Entitlement Offer, which sought to raise up to AU$17.1 million, closed with a shortfall of approximately AU$11.3 million. The funds raised will support ongoing clinical development, commercialisation of NUZ-001, and working capital needs, potentially reducing reliance on its convertible note facility. The company remains on track with its clinical and regulatory milestones and is committed to the HEALEY ALS Platform Trial. Neurizon is positioning NUZ-001 for future commercialization while expanding its focus on broader neurodegenerative diseases.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au